OncoSil Medical Limited (OSL.AX)
AUD 0.01
(-14.29%)
AUD 0.01
(-14.29%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -11.91 Million AUD | -5.03% |
| 2023 | -11.34 Million AUD | -5.74% |
| 2022 | -10.72 Million AUD | -2.81% |
| 2021 | -10.43 Million AUD | -144.81% |
| 2020 | -4.26 Million AUD | 50.25% |
| 2019 | -8.56 Million AUD | -0.32% |
| 2018 | -8.53 Million AUD | -21.71% |
| 2017 | -7.01 Million AUD | -47.13% |
| 2016 | -4.76 Million AUD | -65.63% |
| 2015 | -2.87 Million AUD | 31.73% |
| 2014 | -4.21 Million AUD | -379.67% |
| 2013 | -879.16 Thousand AUD | -104.0% |
| 2012 | -430.97 Thousand AUD | 70.44% |
| 2011 | -1.45 Million AUD | 14.84% |
| 2010 | -1.71 Million AUD | -288.94% |
| 2009 | -440.17 Thousand AUD | 84.09% |
| 2008 | -2.76 Million AUD | -65.3% |
| 2007 | -1.67 Million AUD | -1205.21% |
| 2006 | -128.26 Thousand AUD | -385.49% |
| 2005 | -26.42 Thousand AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 FY | -12.37 Million AUD | -9.1% |
| 2024 Q2 | -6.01 Million AUD | 0.0% |
| 2024 Q4 | -6.35 Million AUD | 0.0% |
| 2023 FY | -11.34 Million AUD | -5.74% |
| 2023 Q4 | -5.69 Million AUD | 0.0% |
| 2023 Q2 | -5.65 Million AUD | 0.0% |
| 2022 FY | -10.72 Million AUD | -2.81% |
| 2022 Q2 | -5.69 Million AUD | 0.0% |
| 2022 Q4 | -5.03 Million AUD | 0.0% |
| 2021 Q4 | -5.68 Million AUD | 0.0% |
| 2021 Q2 | -4.74 Million AUD | 0.0% |
| 2021 FY | -10.43 Million AUD | -144.81% |
| 2020 Q4 | -861.4 Thousand AUD | 0.0% |
| 2020 FY | -4.26 Million AUD | 50.25% |
| 2020 Q2 | -3.4 Million AUD | 0.0% |
| 2019 FY | -8.56 Million AUD | -0.32% |
| 2019 Q4 | -3.41 Million AUD | 0.0% |
| 2019 Q2 | -5.14 Million AUD | 0.0% |
| 2018 Q4 | -4 Million AUD | 0.0% |
| 2018 FY | -8.53 Million AUD | -21.71% |
| 2018 Q2 | -4.53 Million AUD | 0.0% |
| 2017 Q2 | -3.11 Million AUD | 0.0% |
| 2017 FY | -7.01 Million AUD | -47.13% |
| 2017 Q4 | -3.9 Million AUD | 0.0% |
| 2016 FY | -4.76 Million AUD | -65.63% |
| 2016 Q2 | -1.77 Million AUD | 0.0% |
| 2016 Q4 | -2.99 Million AUD | 0.0% |
| 2015 FY | -2.87 Million AUD | 31.73% |
| 2015 Q4 | -422.89 Thousand AUD | 0.0% |
| 2015 Q2 | -2.45 Million AUD | 0.0% |
| 2014 Q4 | -4.86 Million AUD | 0.0% |
| 2014 FY | -4.21 Million AUD | -379.67% |
| 2014 Q2 | -1.99 Million AUD | 0.0% |
| 2013 Q4 | -729.12 Thousand AUD | -231.73% |
| 2013 Q1 | -107.74 Thousand AUD | 0.0% |
| 2013 Q2 | -150.04 Thousand AUD | -39.27% |
| 2013 Q3 | -219.79 Thousand AUD | -46.48% |
| 2013 FY | -879.16 Thousand AUD | -104.0% |
| 2012 Q2 | -107.74 Thousand AUD | 70.44% |
| 2012 FY | -430.97 Thousand AUD | 70.44% |
| 2012 Q3 | -107.74 Thousand AUD | 0.0% |
| 2012 Q1 | -364.5 Thousand AUD | 0.0% |
| 2012 Q4 | -107.74 Thousand AUD | 0.0% |
| 2011 Q1 | -428 Thousand AUD | 0.0% |
| 2011 Q3 | -364.5 Thousand AUD | 0.0% |
| 2011 FY | -1.45 Million AUD | 14.84% |
| 2011 Q4 | -364.5 Thousand AUD | 0.0% |
| 2011 Q2 | -364.5 Thousand AUD | 14.84% |
| 2010 Q3 | -428 Thousand AUD | 0.0% |
| 2010 Q2 | -428 Thousand AUD | -288.94% |
| 2010 FY | -1.71 Million AUD | -288.94% |
| 2010 Q4 | -428 Thousand AUD | 0.0% |
| 2010 Q1 | -110.04 Thousand AUD | 0.0% |
| 2009 FY | -440.17 Thousand AUD | 84.09% |
| 2009 Q4 | -110.04 Thousand AUD | 0.0% |
| 2009 Q1 | -691.82 Thousand AUD | 0.0% |
| 2009 Q2 | -110.04 Thousand AUD | 84.09% |
| 2009 Q3 | -110.04 Thousand AUD | 0.0% |
| 2008 Q2 | -691.82 Thousand AUD | -65.3% |
| 2008 Q1 | -418.53 Thousand AUD | 0.0% |
| 2008 FY | -2.76 Million AUD | -65.3% |
| 2008 Q4 | -691.82 Thousand AUD | 0.0% |
| 2008 Q3 | -691.82 Thousand AUD | 0.0% |
| 2007 Q4 | -418.53 Thousand AUD | 0.0% |
| 2007 Q2 | -418.53 Thousand AUD | -1205.21% |
| 2007 Q1 | -32.06 Thousand AUD | 0.0% |
| 2007 FY | -1.67 Million AUD | -1205.21% |
| 2007 Q3 | -418.53 Thousand AUD | 0.0% |
| 2006 FY | -128.26 Thousand AUD | -385.49% |
| 2006 Q4 | -32.06 Thousand AUD | 0.0% |
| 2006 Q2 | -32.06 Thousand AUD | -385.49% |
| 2006 Q1 | -6605.00 AUD | 0.0% |
| 2006 Q3 | -32.06 Thousand AUD | 0.0% |
| 2005 FY | -26.42 Thousand AUD | 0.0% |
| 2005 Q3 | -6605.00 AUD | 0.0% |
| 2005 Q2 | -6605.00 AUD | 0.0% |
| 2005 Q4 | -6605.00 AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| 4DMedical Limited | -35.97 Million AUD | 66.887% |
| Adherium Limited | -10.22 Million AUD | -16.524% |
| Aroa Biosurgery Limited | -9.74 Million AUD | -22.213% |
| Atomo Diagnostics Limited | -6.84 Million AUD | -73.977% |
| Anteris Technologies Ltd | -67.33 Million AUD | 82.307% |
| Control Bionics Limited | -5.91 Million AUD | -101.455% |
| CardieX Limited | -6.76 Million AUD | -76.097% |
| Compumedics Limited | -338 Thousand AUD | -3424.743% |
| Cochlear Limited | 356.8 Million AUD | 103.339% |
| CleanSpace Holdings Limited | -3.12 Million AUD | -280.975% |
| Cyclopharm Limited | -4.7 Million AUD | -153.438% |
| EMVision Medical Devices Ltd | -2.72 Million AUD | -336.459% |
| Nova Eye Medical Limited | -8.79 Million AUD | -35.536% |
| HeraMED Limited | -6.78 Million AUD | -75.622% |
| Imricor Medical Systems, Inc. | -22.62 Million AUD | 47.345% |
| ImpediMed Limited | -19.79 Million AUD | 39.8% |
| InhaleRx Limited | -1.44 Million AUD | -725.46% |
| LBT Innovations Limited | -3.74 Million AUD | -218.546% |
| Micro-X Limited | -9.76 Million AUD | -22.003% |
| Neurotech International Limited | -5.06 Million AUD | -135.018% |
| PolyNovo Limited | 5.26 Million AUD | 326.452% |
| Respiri Limited | -7.12 Million AUD | -67.109% |
| SomnoMed Limited | -12.24 Million AUD | 2.68% |
| Universal Biosensors, Inc. | -6.74 Million AUD | -76.719% |
| Uscom Limited | -2.07 Million AUD | -474.22% |
| Visioneering Technologies, Inc. | -5.06 Million AUD | -135.293% |